PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.

Abstract The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tumor-infiltrating lymphocytes are promising further predictive utility in view of novel immune-related therapeutic strategies which are coming into the clinical setting launching a solid rationale for the future next-generation treatment options. In this scenario, tumor-infiltrating lymphocytes might represent an important resource for the selection of the most appropriate therapeutic strategy, as well as further evaluations of the molecular mechanisms underlying tumor-infiltrating lymphocytes and the immunoediting process would eventually provide new insights to augment therapeutic success. Considering these perspectives, we review the potential utility of tumor-infiltrating lymphocytes in the definition of breast cancer prognosis and in the prediction of treatment outcomes, along with the new promising molecular-based therapeutic discoveries.
PMID
Related Publications

Evaluation of the immune infiltrate in breast cancer.

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.

Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.

Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.

Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.

Authors

Mayor MeshTerms
Keywords

Tumor-infiltrating lymphocytes

breast cancer

cancer immunotherapy

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28378631
OWN - NLM
STAT- MEDLINE
DA  - 20170405
DCOM- 20170410
LR  - 20170410
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 4
DP  - 2017 Apr
TI  - Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and
      predictive utility.
PG  - 1010428317695023
LID - 10.1177/1010428317695023 [doi]
AB  - The importance of the immune system as a potent anti-tumor defense has been
      consolidated in recent times, and novel immune-related therapies are today
      demonstrating a strong clinical benefit in the setting of several solid
      neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to
      eradicate malignancies, and during the last decades, they have been shown to
      possess an interesting prognostic utility for breast cancer, especially in case
      of HER2 positive and triple-negative molecular subtypes. In parallel, the
      clinical evaluation of tumor-infiltrating lymphocytes has been shown to
      effectively predict treatment outcomes in both neoadjuvant and adjuvant settings.
      Currently, tumor-infiltrating lymphocytes are promising further predictive
      utility in view of novel immune-related therapeutic strategies which are coming
      into the clinical setting launching a solid rationale for the future
      next-generation treatment options. In this scenario, tumor-infiltrating
      lymphocytes might represent an important resource for the selection of the most
      appropriate therapeutic strategy, as well as further evaluations of the molecular
      mechanisms underlying tumor-infiltrating lymphocytes and the immunoediting
      process would eventually provide new insights to augment therapeutic success.
      Considering these perspectives, we review the potential utility of
      tumor-infiltrating lymphocytes in the definition of breast cancer prognosis and
      in the prediction of treatment outcomes, along with the new promising
      molecular-based therapeutic discoveries.
FAU - Ravelli, Andrea
AU  - Ravelli A
AD  - 1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e
      Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Roviello, Giandomenico
AU  - Roviello G
AD  - 3 Section of Pharmacology and University Center DIFF-Drug Innovation Forward
      Future, Department of Molecular and Translational Medicine, Universita degli
      Studi di Brescia, Brescia, Italy.
FAU - Cretella, Daniele
AU  - Cretella D
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Cavazzoni, Andrea
AU  - Cavazzoni A
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Biondi, Alessandra
AU  - Biondi A
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Cappelletti, Maria Rosa
AU  - Cappelletti MR
AD  - 1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e
      Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
FAU - Zanotti, Laura
AU  - Zanotti L
AD  - 1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e
      Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
FAU - Ferrero, Giuseppina
AU  - Ferrero G
AD  - 4 Department of Anatomical Pathology, AO Azienda Istituti Ospitalieri di Cremona,
      Cremona, Italy.
FAU - Ungari, Marco
AU  - Ungari M
AD  - 4 Department of Anatomical Pathology, AO Azienda Istituti Ospitalieri di Cremona,
      Cremona, Italy.
FAU - Zanconati, Fabrizio
AU  - Zanconati F
AD  - 5 Department of Medical, Surgery and Health Sciences, Universita degli Studi di
      Trieste, Trieste, Italy.
FAU - Bottini, Alberto
AU  - Bottini A
AD  - 1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e
      Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
FAU - Alfieri, Roberta
AU  - Alfieri R
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Petronini, Pier Giorgio
AU  - Petronini PG
AD  - 2 Unit of Experimental Oncology, Department of Clinical and Experimental
      Medicine, Universita degli Studi di Parma, Parma, Italy.
FAU - Generali, Daniele
AU  - Generali D
AD  - 1 UO Multidisciplinare di Patologia Mammaria, US Terapia Molecolare e
      Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
AD  - 5 Department of Medical, Surgery and Health Sciences, Universita degli Studi di
      Trieste, Trieste, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
SB  - IM
MH  - Breast Neoplasms/classification/immunology/*therapy
MH  - Female
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Neoadjuvant Therapy
MH  - Prognosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - *Tumor-infiltrating lymphocytes
OT  - *breast cancer
OT  - *cancer immunotherapy
EDAT- 2017/04/06 06:00
MHDA- 2017/04/11 06:00
CRDT- 2017/04/06 06:00
AID - 10.1177/1010428317695023 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Apr;39(4):1010428317695023. doi: 10.1177/1010428317695023.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>